Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-reviewed Scientific Journal
Halifax, Nova Scotia – (Newsfile Corp. – January 13, 2025) – Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology. This research article includes new follow-up data which provides a comprehensive analysis of the immunity activated by Sona’s Targeted Hyperthermia Therapy (“THT”). The published manuscript titled, “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” is available online in electronic form here and will be in print in its upcoming issue of Frontiers in Immunology – Cancer Immunology and Immunotherapy. Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
